Mycal Casey, DO, MPH,

Hem/Onc fellow @GeorgetownHOF🩸🦀 #SpartanDO📚#MSUPublicHealth @MCG_InternalMed👨🏻‍⚕️ Interested in Myeloid Malignancies #leusm and Transplant #bmtsm

[Mycal Casey, DO, MPH, @MycalCasey]

It is official, next stop PNW 🏔️

[OncUpdates @OncUpdates]

⭐️ #ASH2025 Highlights with @MycalCasey and Dr.Maiti

🔷Bispecifics like blina have entered frontline setting for ALL
🔷CAR-T updates
🔷 TP53-mutated AML/MDS alternatives (HMA+Ven) offer better tolerability over intensive chemo

#MedTwitter

Full 🗣️👇
https://t.co/NPgN8F1x72

[Stephen V Liu, MD @StephenVLiu]

We are growing & looking for several hematologists at @MedStarGUH @LombardiCancer in Washington, DC! Details below!

- Multiple Myeloma
https://t.co/z8Vj5XSTJq

- BMT Transplant and Cell Therapy
https://t.co/WeDwMRs21f

- Leukemia
https://t.co/bIToyvSUlX

[Mycal Casey, DO, MPH, @MycalCasey]

Aquila did not have adequate crossover to prove that in 2025 there would be benefit of treating SMM. When the standard of care is a quad w/ anti-CD38. To say that Dara was beneficial for SMM but the control group only had a fraction receive the drug on progression is incomplete.

[Vincent Rajkumar @VincentRK]

Daratumumab is the standard of care for high risk smoldering myeloma, and should be considered as Option 1 (if available) after discussing pros and cons. It’s limited duration therapy that is approved by the FDA, and is approved in Europe.

Observation alone is fraught with risk even in the best of centers. Patients find it hard to get appointments to see doctors and specialists and get the right monitoring done to prevent end organ damage. So while that option is OK for certain patients, if that option is chosen please watch closely like the control arm of AQUILA (easier said than done) and as with dara, do so after discussing pros and cons.

In my experience after doing many chart reviews and reviewing lots of lots of patient records, many physicians are super confident of being able to watch closely and prevent serious end organ damage but the reality is different.

https://t.co/3hC2E6tnxQ

[Mycal Casey, DO, MPH, @MycalCasey]

PGY-VI

[Mycal Casey, DO, MPH, @MycalCasey]

Victory lap weekend with @TinaRoyMD . We both worked the very first weekend of fellowship, and today we are finishing.

[Mycal Casey, DO, MPH, @MycalCasey]

@GCC_Cortes @BloodGlobalHema @BloodPortfolio @ASH_hematology @GACancerCenter I love the range of disciplines in this

[Jorge Cortes MD @jorgecortesmd]

The first issue of @BloodGlobalHema is out with great hematology research from all other the world. @BloodPortfolio @ASH_hematology @GACancerCenter

[Mycal Casey, DO, MPH, @MycalCasey]

Seeing that end date on my last contract for training is surreal. One year to go!

[Mycal Casey, DO, MPH, @MycalCasey]

@chulkimMD @TinaRoyMD strong work 💪

[Mycal Casey, DO, MPH, @MycalCasey]

@Chauhan_AF This is perfect!

[Mycal Casey, DO, MPH, @MycalCasey]

I need a drug company to have a clinical trial theme with espresso drinks. Latte-2, cappuccino-1, etc.

Then during medical decision making we can say “based on Cortado-5…”

[Mycal Casey, DO, MPH, @MycalCasey]

Tree outside our door is full bloom

[Mycal Casey, DO, MPH, @MycalCasey]

Finishing out the last few days on the Oncology consult service!

[Mycal Casey, DO, MPH, @MycalCasey]

@allisonoconn You had time to get lunch before noon conference 😅

[Mycal Casey, DO, MPH, @MycalCasey]

Snow Day ❄️ ⛄️

[Mycal Casey, DO, MPH, @MycalCasey]

Half-way through fellowship, 18 months to go!

[Mycal Casey, DO, MPH, @MycalCasey]

AQUILA: Only 18% of control arm received Dara. The CI for this was 0.27 to 0.98

It’s hard to believe there would OS benefit in 2024,when most patients have Dara with tx. Also unlikely to be statistical significance if there was more crossover.

Not to mention other limitations

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm

Few important observations on AQUILA

This is in top of prior observations I shared

🧵

[Mycal Casey, DO, MPH, @MycalCasey]

Great crew, well deserved!

[MCG Cardiology Fellowship @MCGCardFellows]

Excited for our 3rd year fellows all matching at their top choices for advanced fellowship! @KayShahbazian @drgemmohan @docakshatm Khalil Jalkh and Walker Barmore. #fellowshipmatch

@Deya_AlkhatibMD @aroravis @MusaSharkawiMD

[Mycal Casey, DO, MPH, @MycalCasey]

@KayShahbazian @OchsnerCVFellow Congrats!!